Contemporary Amperex Technology Co. Ltd. (CATL), a company directly funded and supported by the Chinese Communist Party, continues to pose national security risks to the United States. This past spring, CATL batteries were installed at Camp Lejeune, North...
U.S. Senator Marco Rubio’s (R-FL) office will host in-person Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
A mysterious respiratory illness is once again spreading in China. Until we know more about what could be a new pathogen, the United States must do everything possible to prevent the illness from reaching our shores. U.S. Senator Marco Rubio (R-FL) and colleagues sent...
Una misteriosa enfermedad respiratoria se está propagando una vez más en China. Hasta que sepamos más sobre lo que podría ser un nuevo patógeno, EE.UU. debe hacer todo lo posible para evitar que la enfermedad llegue a nuestras costas. El senador estadounidense Marco...
El 21 de diciembre del 2023 expirarán las sanciones del gobierno de EE.UU. contra el narco-dictador venezolano Nicolás Maduro y 150 miembros de su régimen criminal, quienes son responsables de abusos contra los DDHH. del pueblo venezolano. El senador estadounidense...
On December 21, 2023, the U.S. government’s sanctions against Venezuela’s narco-dictator Nicolás Maduro, and 150 members of his criminal regime responsible for human rights abuses against the Venezuelan people, will expire. U.S. Senator Marco Rubio (R-FL)...
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Chris Coons (D-DE) introduced the Agility in Manufacturing Preparedness Act (S.3553) to require the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for the purpose of evaluating the current capacity and vulnerabilities of biopharmaceutical manufacturing in the United States. NIIMBL is a public-private partnership focused on improving manufacturing capabilities through its cutting-edge expertise, which would help the federal government enhance its preparedness and response capabilities for emerging public health threats. Rubio and Coons first introduced this bill as an amendment (#1917) to the Senate’s Endless Frontier Act in May 2021.
“America needs to be able to make things again, especially medicine,” Rubio said. “My new bill will help bring that back.”
“The current global health crisis has once again underscored the importance of sustained attention to potential threats and our preparedness for them. Expanding our manufacturing capacity in the United States and ensuring that it can respond to a variety of threats is imperative,” Coons said. “The Agility in Manufacturing Preparedness Act will put us in a position to improve our medical preparedness and support America’s health.”
The legislation specifically requires NIIMBL, in partnership with HHS, to: